39 patents currently held

240 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

5 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Of the 240 now held by other companies, 83 name Takeda Pharmaceutical Company Limited as their current owner, and 157 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Dec 2026

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 20412042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Cleavable Lipids US 9,717,690

Cited by 147 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.

Ends Feb 2033 · High confidence Also notable

Mrna for Use in Treatment of Human Genetic Diseases US 8,853,377

The most cited patent in this portfolio, cited by 213 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2031.

Ends Nov 2031 · High confidence Also notable

Peptide Linkers for Polypeptide Compositions and Methods for Using Same US 8,580,922

Cited by 55 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.

Ends Jun 2031 · High confidence

Formerly held, still cited

Notable

Liver Specific Delivery of Messenger RNA US 10,143,758

The most cited patent in this portfolio, cited by 261 later US patents, top 1% of utility patents granted in 2018 in our data. Protection runs to 2032.

now held by Translate Bio, Inc.

Ends Mar 2032 · Medium confidence

Also notable

Mrna Therapy for Fabry Disease US 9,308,281

Cited by 125 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.

now held by Translate Bio, Inc.

Ends no later than Jun 2032 · Low confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 27, 2026
The maintenance fee for Maribavir Isomers, Compositions, Methods of Making and Methods of Using (US 11,684,632) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
1 fee due Apr 17, 2027
The maintenance fee for Plasma Kallikrein Inhibitors and Uses Thereof (US 11,787,796) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
2 fees due May 26, 2027
2 fees due Jun 8 to 24, 2027 · next Jun 8
1 fee due Aug 25, 2027
The maintenance fee for Treatment of Cognitive Impairment of Hunter Syndrome by Intrathecal Delivery of IDURONATE-2-Sulfatase (US 10,568,941) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
1 fee due Sep 26, 2027
The maintenance fee for Compositions and Methods Useful for the Treatment of Neuromyelitis Optica Spectrum Disorders (US 11,938,174) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
1 fee due Oct 30, 2027
The maintenance fee for Antibody-Resin Coupling Apparatus and Methods (US 11,969,703) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026
2 terms have ended since Aug 16, 2026

What they patent

The 5 largest of its 26 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Maribavir Isomers, Compositions, Methods of Making and Methods of Using	4 in force	to Jun 2032
Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases	3 in force	to Oct 2032
Peptide Linkers for Polypeptide Compositions and Methods for Using Same	3 in force	to Nov 2031
Antibody-Resin Coupling Apparatus and Methods	2 in force	to Aug 2039
ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy	2 in force	to Jun 2036

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 10,583,146	Pharmaceutical Compositions for Glucocorticoid Replacement Therapy held by Shire Viropharma LLC In force Ends no later than Dec 17, 2026 · Medium confidence	In force	Ends no later than Dec 17, 2026	Medium confidence
US 8,425,937	Pharmaceutical Compositions for Glucocorticoid Replacement Therapy held by Shire Viropharma LLC In force Term ends Jan 22, 2028 · High confidence	In force	Term ends Jan 22, 2028	High confidence
US 9,463,222	Methods for Treatment of Complications of Prematurity Comprising Administration of Igf-I and IGFBP-3 held by Shire Human Genetic Therapies, Inc. In force Ends no later than Apr 18, 2028 · Low confidence	In force	Ends no later than Apr 18, 2028	Low confidence
US 8,518,877	Method and Product for Treatment And/Or Prevention of Complications of Prematurity held by Shire Human Genetic Therapies, Inc. In force Term ends Mar 31, 2030 · High confidence	In force	Term ends Mar 31, 2030	High confidence
US 8,371,092	Apparatus and Methods for Reducing Capsule Elongation held by Shire Viropharma LLC In force Term ends Dec 7, 2030 · High confidence	In force	Term ends Dec 7, 2030	High confidence
US 8,580,922	Peptide Linkers for Polypeptide Compositions and Methods for Using Same held by Shire Human Genetic Therapies, Inc. In force Term ends Jun 25, 2031 · High confidence	In force	Term ends Jun 25, 2031	High confidence
US 9,206,235	Peptide Linkers for Polypeptide Compositions and Methods for Using Same held by Shire Human Genetic Therapies, Inc. In force Ends no later than Jul 19, 2031 · Medium confidence	In force	Ends no later than Jul 19, 2031	Medium confidence
US 10,765,692	Maribavir Isomers, Compositions, Methods of Making and Methods of Using held by Shire Viropharma LLC In force Term ends Oct 27, 2031 · Medium confidence	In force	Term ends Oct 27, 2031	Medium confidence
US 11,130,777	Crystalline Phases of 5,6-Dichloro-2-(ISOPROPYLAMINO)-(1-BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE held by Shire Viropharma LLC In force Term ends Oct 27, 2031 · High confidence	In force	Term ends Oct 27, 2031	High confidence
US 8,546,344	Crystalline Phases of 5,6-Dichloro-2-(ISOPROPYLAMINO)-1-ß-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE held by Shire Viropharma LLC In force Term ends Nov 9, 2031 · High confidence	In force	Term ends Nov 9, 2031	High confidence

10 of 39 patents shown.

Pro members see all 39.

Pro members: see all 39 patents

Also on record, not counted in the 39: 240 patents in force now held by others · 100 patents ended · 48 applications pending · 277 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Shire LLC